Ownership and insider activity for Armata Pharmaceuticals, Inc. (ARMP): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections that have developed resistance to standard antibiotics. The company's innovative treatments are developed utilizing its exclusive bacteriophage-based technology platform.
Price
| Price | $4.07 |
| Market Cap | $149M |
| Exchange | AMEX |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-07-10 | Birx Deborah | F-InKind | 14,041 | $60K |
| 2026-04-24 | Gilmer Daniel B. | A-Award | 51,280 | $663K |
| 2026-04-24 | Gilmer Daniel B. | |||
| 2026-03-14 | Kyme Pierre | F-InKind | 1,030 | $11K |
| 2026-03-14 | Birx Deborah | F-InKind | 4,919 | $52K |
| 2026-03-09 | Kramer Robin | A-Award | 25,640 | $298K |
| 2026-03-09 | Kyme Pierre | A-Award | 183,142 | $2.1M |
| 2026-03-09 | House David Duane | A-Award | 109,885 | $1.3M |
| 2026-03-09 | PATTI JOSEPH M | A-Award | 25,640 | $298K |
| 2026-03-09 | Peterson Todd C. | A-Award | 25,640 | $298K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.7M | $5.1M | $8.2M | $6.0M | $9.6M | $10.3M | $14.9M | $13.5M | $9.3M | $8.7M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $25000 | 0 | 0 | 0 | $561000 | $3.0M | $8.5M | $3.4M | $744000 | $472000 |
| Inventory | -$619000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $6.4M | $5.4M | $8.4M | $6.7M | $10.8M | $15.0M | $27.0M | $19.2M | $11.3M | $10.7M |
| Property, Plant & Equipment | $1.1M | $816000 | $503000 | $4.2M | $12.8M | $38.1M | $46.7M | $57.3M | $54.9M | $46.1M |
| Goodwill | 0 | 0 | 0 | $3.5M | $3.5M | $3.5M | $3.5M | $3.5M | $3.5M | $3.5M |
| Intangible Assets | $10.8M | $4.9M | $3.0M | $10.3M | $10.3M | $10.3M | $10.3M | $10.3M | $10.3M | $10.3M |
| Total Assets | $18.2M | $11.1M | $11.9M | $25.5M | $39.5M | $69.8M | $107.9M | $98.4M | $86.4M | $76.9M |
| Accounts Payable | $1.1M | $578000 | $729000 | $547000 | $956000 | $1.1M | $1.7M | $1.6M | $766000 | $921000 |
| Short-term Debt | $803000 | 0 | 0 | $1.3M | $722000 | 0 | 0 | 0 | $39.0M | 0 |
| Total Current Liabilities | $3.6M | $2.0M | $2.6M | $4.9M | $6.7M | $4.8M | $24.9M | $16.5M | $48.2M | $8.9M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $82.3M | $55.4M | $256.9M |
| Total Liabilities | $8.5M | $3.4M | $3.4M | $10.9M | $20.7M | $44.4M | $71.8M | $130.4M | $134.5M | $295.5M |
| Retained Earnings | -$381.4M | -$394.2M | -$406.3M | -$157.5M | -$179.7M | -$202.9M | -$239.8M | -$308.8M | -$327.7M | -$501.5M |
| Total Equity | $9.7M | $7.7M | $8.5M | $14.6M | $18.9M | $25.4M | $36.1M | -$32.1M | -$48.0M | -$218.6M |
| Total Debt | $803000 | 0 | 0 | $2.9M | $13.2M | $38.0M | $48.8M | $120.4M | $126.5M | $288.0M |
| Net Debt | -$4.9M | -$5.1M | -$8.2M | -$3.2M | $3.5M | $27.7M | $34.0M | $106.8M | $117.2M | $279.3M |
| Working Capital | $2.8M | $3.4M | $5.8M | $1.8M | $4.1M | $10.2M | $2.2M | $2.7M | -$36.9M | $1.7M |
Financial Health
| Debt / Equity | -1.36 |
| Current Ratio | 0.11 |
Profitability
| Return on Equity | 89.70% |
| Return on Invested Capital | -47.40% |
| Return on Assets | -213.65% |
| Gross Margin | 68.23% |
| Operating Margin | -1233.59% |
| Net Margin | -5825.34% |
Related companies: CCCC · CDXS · GNFT · IMDX · IPHA · NTHI · NVCT
Explore sector: Healthcare · Biotechnology
More sections of ARMP: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks